【文档说明】产碳青霉烯酶肺炎克雷伯菌治疗课件.ppt,共(15)页,560.500 KB,由小橙橙上传
转载请保留链接:https://www.ichengzhen.cn/view-246508.html
以下为本文档部分文字说明:
产碳青霉烯酶肺炎克雷伯菌治疗桂林医学院附属医院微生物中的“收藏家”虽然不是对抗生素天然耐药,但因为只产适量的青霉素酶染色体,被称为臭名昭著的“多耐药质粒的收藏家”桂林医学院附属医院桂林医学院附属医院耐药进程桂林医
学院附属医院泛耐药CRKP桂林医学院附属医院Clinicalstudies,antimicrobialtherapies,andoutcomesforpatientsinfectedwithKPC-producingK.pneumoniaeReferenceCountry
(yrofpublication)StudydesignNo.ofpatientswithindicatedinfectionTypeofβ-lactamase(no.ofisolates)Treatmentwithactivedrug(no.ofpatients
)Outcome(no.ofsuccesses/no.offailures)182USA(2009)Caseseries3BSIsKPC-2(3)Tetracycline-aminoglycoside(1)1/0Colistin(
3)1/2175Greece(2010)Case-controlstudy19BSIsKPC-2(19)Colistin(10)2/8162China(2008)Tigecycline-aminoglycoside(1)1/0Colistin-ami
noglycoside(9)4/5274Greece(2011)Case-controlstudy53BSIsKPC-2(53)Carbapenem(1)0/1Colistin(7)3/4Tigecycline(5)3/2Aminoglycos2/0桂林医学院附属医院Clinic
alstudies,antimicrobialtherapies,andoutcomesforpatientsinfectedwithMβL-producingK.pneumoniaeReferenceCountry(yrofpubl
ication)StudydesignNo.ofpatientswithindicatedtypeofinfectionTypeofMBL(no.ofisolates)Treatment(no.ofpatients)Outcome(no.ofsuccesses/n
o.offailures)86Greece(2008)Tigecycline(1)1/056Spain(2008)Tigecycline-colistin(2)1/1269Taiwan(2001)Caseseries3BSIsIMP-8(3)Carbapenem(
3)1/2143Taiwan(2004)Caseseries3(2pneumonias,1BSI)IMP-typeenzyme(3)Carbapenem(1)1/0240Greece(2008)Caseseries17(14BSIs,3pneumonias)VIM-1(1
7)Colistin(6)6/0Tigecycline(1)0/1175Greece(2010)Case-controlstudy18BSIsVIM-1(17)Colistin(10)6/4桂林医学院附属医院RegimenA,combinationtherapywith≥2ac
tivedrugs,oneofwhichwasacarbapenem;regimenB,combinationtherapywith≥2activedrugs,notincludingacarbapenem;regimenC,monothe
rapywithanaminoglycoside;regimenD,monotherapywithacarbapenem;regimenE,monotherapywithtigecycline;regim
enF,monotherapywithcolistin;regimenG,inappropriatetherapy.RegimenAwassuperiortoregimensB,E,F,andG(forAversusB,E,F,andG,thePvaluewas0.02,0.03
,<0.0001,and<0.0001,respectively).RegimensB,C,andDweresuperiortoregimenG(forBversusG,P=0.014;forCversusG,P=0.04;andforDversusG,P=0.03).桂林
医学院附属医院分析•Thedecreasedclinicaleffectivenessoftigecyclineinsevereinfectionscouldbeattributedpartlytothepharmacokinetic/ph
armacodynamic(PK/PD)profileofthedrug.•替加环素在严重感染中的临床疗效减少,可能是由于药物的PK/PD•PK/PD:对不同类抗菌药物给药方案具有指导意义桂林医学院附属医院•Tigecyclinedemonstratesmainlybacteriosta
ticactivityagainstGram-negativeorganisms,andtheattainabledrugconcentrationsatseveralanatomicsitesaresuboptimal.•替加环素对革兰氏阴性菌主要是抑菌效果
•theattainabledrugconcentrationsatseveralanatomicsitesaresuboptimal•在体外药效学模式中,随着浓度超过1mg/L时,其抑菌作用保持不变,因此实
现药物浓度是次重要的桂林医学院附属医院•Thepeakserumconcentrationsachievedwiththestandarddosingregimenofthedrug(50mgtwiced
aily)rangefrom0.6to0.9μg/mlwhilethoseattainedintheurineandintheepithelialliningfluidareseveralfoldlower•按照
替加环素的标准给药方案(50mgq12)当血药浓度达到峰值时(0.6to0.9μg/ml),其尿液和上皮表面液体中的浓度则非常低桂林医学院附属医院•Thedrugconcentrationsattainablebythisstandarddosingregimen,comb
inedwiththisdrug'sMICprofileforcurrentCPEisolates,renderitunlikelyfortigecyclinetocureCPEinfectionsatanatomicsiteswheredrugconcentrationsaresubopt
imal.•替加环素在某些部位浓度很低,且不足以达到抑菌浓度。当CPE感染在这些部位时,则很难达到疗效。•这使得替加环素不太可能治愈CPE在这些部位的严重感染桂林医学院附属医院结论•Therefore,thisd
rugshouldbeusedwithcautionagainstCPE,preferentiallyincombinationwithanotheractiveagentandafterdueconsiderationoftheattainabledrugconcentrationat
theanatomicsiteofinfectionandoftheMICfortheinfectingorganism.•因此,替加环素在对待产碳青霉烯酶肠杆菌(CPE)时须谨慎使用。•综合考虑替加环素在感染部位的浓度以及其最低抑菌浓度•优先结合另一个活性药物。桂林医学院附属医
院谢谢聆听!2020/11/515谢谢观赏!